Professionals with Perspective

James G. Cullem, J.D., B.S. (Founder & Managing Principal): Jim brings
to the table a depth of experience that combines intellectual property asset and strategy expertise with the invaluable perspective of seasoned corporate senior manager ensuring I.P. strategy alignment with corporate business strategies. He is a registered patent attorney and intellectual property (I.P.) expert, with over a decade of experience in I.P. strategy development and implementation, and I.P. asset acquisition, management, and leveraging in
the biotechnology/life sciences sector. He has consulted for early-stage companies in the pharmaceutical, diagnostic, reagent, and medical device sectors. Jim spent seven years in-house as the Chief I.P. Counsel &
Director of Licensing at Cell Signaling Technology, Inc., where he oversaw global patent, trademark, trade secret, licensing, and collaboration/alliance strategy & activities. Prior to his in-house role, he served several years as a biotechnology patent attorney with the intellectual property group of Mintz Levin P.C. (Boston, MA). His I.P. experience extends to a broad array of biotechnologies, including proteomics, biomarkers, novel drug targets,
genes, discovery methods, and medical devices. He holds a B.S. in Biochemistry (with graduate coursework in toxicology) and has worked
within the life sciences field for 20 years, including several years at the
bench with Chiron Corporation and the J. David Gladstone Institutes. Jim is an Editor of the Journal of Commercial Biotechnology, a former Co-Chair of the BPLA Corporate Practice Committee, and sits of the I.P. Advisory Board
at the Pierce Law School. He has frequently lectured on I.P. asset development and management issues.
Contact: James Cullem

Christopher F. Dippel, M.S. (Senior Consultant): Chris brings more
than 20 years of experience in biotech business development and academic technology licensing, including serving as an independent advisor to early stage companies and organizations in the life and healthcare sciences.
He has completed projects in policy development, business planning, marketing, transactions, and licensing for clients ranging from biotech
start-ups, to major companies, to significant non-profits.  Prior to his consulting career, he was the Director of Business Development at both Modular Genetics, Inc. and GlycoFi, Inc., and the Director of Technology Licensing for Wyeth Pharmaceuticals, Inc., where he worked closely with the drug discovery groups.  Earlier in his career, Chris served as a Technology Transfer Officer at New England Medical Center, Boston Children’s Hospital, and Harvard Medical School.  He presently serves as Associate Director of a Massachusetts Institute of Technology (M.I.T.)/Harvard graduate course
on innovation in global health, as a Mentor in M.I.T.’s Venture Mentoring Service, and as a Principal at First Founders, Ltd., a non-profit startup which provides new ventures with seasoned management.  He holds an undergraduate degree in biology from M.I.T. and Masters degrees in physiology from the Universities of Idaho and Kansas.
Contact: Christopher Dippel

Karen Hersey, J.D., B.A. (Senior Consultant): Karen has more than
20 years experience as an intellectual property attorney and university technology transfer expert. She spent much of that time at the Massachusetts Institute of Technology (M.I.T.), where she began as a technology licensing officer in 1980 and ultimately served as Senior Counsel for Intellectual Property. While serving in academia, she was an active participant in developing many of the current best practices used today in academic technology transfer in the U.S. In addition to the traditional technology transfer activities associated with I.P. licensing to existing and start-up/spin-out companies, Karen’s unique experience as an I.P. attorney engaged early-on in the development of academic licensing has enabled
her to develop strategies for building effective knowledge asset management capacities in academia, both from organizational and operational
perspectives. She currently serves as a Visiting Professor at the Franklin Pierce Law Center, Concord, N.H., where she teaches courses on technology transfer and knowledge asset management in the university setting, and lectures and consults for universities and governmental organizations
around the world. She is a former president of the Association of University Technology Managers (AUTM), and continuing her interest and commitment
to developing effective strategies for the transfer of university intellectual property assets, serves on numerous academic intellectual property advisory boards and programmatic committees. In addition to numerous publications, she is currently co-authoring an international work on universities and the commercialization of research, scheduled for publication in 2009 by
Cambridge University Press.
Contact: Karen Hersey

Paul Hippenmeyer, Ph.D., M.B.A.  (Senior Consultant): Paul brings over
20 years of experience in the pharma/biotech drug discovery space,
including senior scientific leadership roles in therapeutic and technology development areas. He was Director of Research at Keel Pharmaceuticals,
Inc. (Cambridge, MA), a start-up drug company targeting autoimmune diseases, where he directed operations and research resulting in the
discovery and characterization of new agonist monoclonal antibodies. Prior
to Keel, he was a Co-Founder of Biosynthecore, LLC, a biocatalysis and medical device company, where he also served as Vice President of Business Development. Earlier in his career, Paul held several research and
development positions at Monsanto, Searle and Pharmacia, including serving as a Fellow and Senior Research Advisor in the oncology area, where he directed research in new target identification and characterization, making heavy use of transcriptional profiling data, cell engineering and gene transfer. He also acted as a Liaison to the Licensing Department, working closely
with research, clinical and commercial colleagues to scout and evaluate new therapeutic licensing opportunities, and as Project Leader for an antiviral
drug discovery program. Paul is an expert in biosafety, having served as Monsanto’s Institutional Biosafety Committee chairperson, where he
ensured global compliance with NIH Guidelines, and previously as a
community representative on St. Louis University’s Institutional Biosafety Committee. He is presently a technical advisor for Global Patent Group, a transactional pharma/biotech patent law firm. Paul holds a Doctorate Degree in Cellular and Molecular Biology from St. Louis University, and an M.B.A.
from University of Missouri-St. Louis.
Contact: Paul Hippenmeyer